Drug News

Calyx and Invicro Merge to Lead Medical Imaging Solutions for Clinical Research

Calyx and Invicro have reached an agreement to merge, forming a global leader in medical imaging and software solutions for the clinical research community. The combined entity will offer comprehensive services spanning the R&D lifecycle, from discovery to post-marketing.

The merger will see Calyx acquiring 100% of Invicro from its current owner, REALM IDx, Inc., subject to regulatory approvals and customary closing conditions, expected to be completed in Q2 2024. With approximately 2,000 employees across ten sites in the US, Europe, and Asia, the Group will provide a full suite of solutions to clients worldwide.

Both Calyx and Invicro bring complementary expertise and extensive experience in supporting clinical and research trials, including oncology and the central nervous system. The merged entity will enhance research and development capabilities, offering scientific and service support in preclinical and exploratory work.

David Herron, CEO of Calyx, expressed excitement about the merger, emphasizing the combined scientific talent, service offerings, and international presence that will establish the Group as an industry leader. Edward Hogan, COO of Invicro, highlighted the opportunity to unite skilled teams to accelerate the development of life-saving therapies across various therapeutic areas.

Following the transaction, efforts will focus on integrating the two companies while ensuring continued high-quality service and support for customers.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker